Trimtech Therapeutics, a Cambridge, UK-based biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, raised $31M in Seed funding.
The round was led by Cambridge Innovation Capital (CIC) and SV Health Investorsā Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also included Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.
The company intends to use the funds to develop its pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.
Led by CEO Nicola Thompson, Trimtech is leveraging the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases which are not well served by current TPD approaches. This new approach harnesses TRIM21ās properties in the form of its TRIMTAC degrader molecules to develop medicines that address the needs of large patient populations with limited treatment options.
The company was founded by CIC and DDF in conjunction with their joint entrepreneur-in-residence, Damian Crowther, and academic co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute at the University of Cambridge).
Trimtech has also appointed the following life science executives to the Board of Directors:
- Michael Anstey, Partner at Cambridge Innovation Capital);
- Laurence Barker, Partner at SV Health Investors (SV);
- Hakan Goker, Managing Director at M Ventures, Jeffrey Moore, President at MP Healthcare Venture Management;
- Marie-Claire Peakman, Partner at Pfizer Ventures.
FinSMEs
05/03/2025